Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2026-01-05 Share Issue/Capital Cha…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Issue of Employee Options 2 pages 185.5KB
Share Issue/Capital Change Classification · 95% confidence The document is an announcement dated 6 January 2026 regarding the issue of 2,500,000 unlisted employee options under the company's Long Term Incentive Plan (LTIP). It references compliance with the Corporations Act 2001 and mentions that an Appendix 3G (a regulatory form related to securities issued to employees) will follow. The content focuses on the issuance of employee options as part of compensation and incentive alignment, not on financial results, management changes, or other report types. The document length is short (3034 characters) and is a regulatory announcement about capital issuance related to employee options. This fits the category of Share Issue/Capital Change (SHA) rather than a full report or other filing types.
2026-01-05 English
Notification regarding unquoted securities - PYC 7 pages 21.1KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted employee options by PYC Therapeutics Limited. It includes specifics such as the number of securities issued, issue date, exercise price, expiry date, and vesting conditions. The document is a formal notification about the issuance of new securities under an employee incentive scheme, which is a capital change event. There is no financial performance data, management discussion, or audit information. The document is not a report but an announcement of a securities issuance event. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (6821 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2026-01-05 English
Issue of Director Options 6 pages 406.2KB
Director's Dealing Classification · 100% confidence The document is an announcement dated 23 December 2025 from PYC Therapeutics Limited regarding the issue of 2,000,000 unlisted director options to a company director. It includes detailed terms and conditions of the director options, such as exercise price, vesting conditions, expiry date, and rights attached to the options. The announcement references compliance with ASX Listing Rule 10.12 exception 12 and mentions that an Appendix 3G and Change of Director Interest Notice will be lodged following this announcement. The content focuses on the issuance of director options, which is a form of director dealing or insider transaction. There is no financial report, earnings data, or management discussion of financial results. The document is not a full annual or interim report, nor is it a regulatory filing or announcement of a report publication. It is a specific announcement about director options issued to a director, which fits the category of Director's Dealing (DIRS).
2025-12-22 English
Notification regarding unquoted securities - PYC 7 pages 21.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unlisted options as incentive securities for an incoming director. It includes specifics such as the number of securities issued, issue date, security type, and compliance with ASX listing rules. The content is a formal notification of a securities issue rather than a financial report, earnings release, or management discussion. This matches the definition of a Share Issue/Capital Change announcement, which covers new share issues or capital changes. Therefore, the document is best classified as a Share Issue/Capital Change (SHA).
2025-12-22 English
Change of Director's Interest Notice - Peter Coleman 2 pages 281.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's acquisition of securities (unlisted options) as part of remuneration, including dates and number of securities before and after the change. The document is a formal notification of a director's personal share transactions. It does not contain financial statements, earnings data, or management discussion. It fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3446 characters, consistent with a short notice rather than a full report. Therefore, the correct classification is DIRS with high confidence.
2025-12-22 English
PKD Clinical Trial - Safety Outcomes in Part A 4 pages 303.4KB
Capital/Financing Update Classification · 90% confidence The document is an announcement dated 19 December 2025 from PYC Therapeutics Limited regarding the safety outcomes of Part A of a Phase 1a/1b clinical trial for their drug candidate PYC-003 targeting Polycystic Kidney Disease. It discusses clinical trial progress, safety review committee findings, and next steps in the drug development pathway. The content is focused on clinical trial updates and safety data rather than financial results, regulatory filings, or management changes. It is not a full financial report, earnings release, or regulatory filing. The document is a detailed update on clinical trial progress and safety outcomes, which is typical of a Capital/Financing Update or clinical progress announcement. Given the focus on clinical trial safety outcomes and development progress, the best fitting category is Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, and often includes clinical trial progress announcements for biotech companies. The document length (6830 characters) and detailed content support this classification rather than a brief announcement or a regulatory filing. Therefore, the classification is CAP with high confidence.
2025-12-18 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.